Results 21 to 30 of about 21,434 (231)

The effects of donepezil in Alzheimer's disease - Results from a multinational trial [PDF]

, 1999
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD).
Hecker, J., Petit, H., Friedhoff, L. T., Rogers, S. L., Burns, A., Gauthier, S., Möller, Hans-Jürgen, Rossor, M.   +7 more
core   +1 more source

DOMINO-AD protocol : donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT [PDF]

, 2009
Background: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has
Ashley Baldwin, Ajay Macharouthu, Juszczak, E, R. Brown (3682735), Raftery, James, Jones Rob, Gray, R, Ballard, C, Burns, Alistair; id_orcid, Adams, Jessica, Knapp, M, Raftery James, J. Adams (7579901), Knapp, Martin, Griffin Mary, Ian McKeith, Baldwin, A, P. Passmore (7608800), Dening, Tom, Griffin, M, S. Banerjee (1503751), B. Sheehan (7608761), Jones Roy, Jones, Roy, T. Dening (7608776), Sube Banerjee, Sheehan, Bart, McShane, R, Patrick Phillips, Bentham, Peter, Findlay David, O'Brien, John, Alistair Burns, Barber, Bob, McShane, Rupert, Brown, R, Ritchie Craig, Dening, T, Hughes, Alan, J. Raftery (7608803), O'Brien John, Richard Brown, Holmes, C, Jessica Adams, Jacoby, Robin, Phillips, Patrick, McShane Rupert, Dening Tom, Clive Holmes, D. Findlay (7608779), Ballard Clive, Bart Sheehan, Rob Jones, Raftery, J, Brown, R. G., McKeith, I, Ritchie, C. W., A. Baldwin (7608767), Ritchie, Craig, P. Phillips (5239541), DOMINO-AD team, Banerjee, S, Ed Juszczak, P. Bentham (7589273), Juszczak, Ed, James. Lindesay (7608785), Robin Jacoby, Alan Hughes, Bob Barber, Richard Gray, Barber, B, Tony Johnson, Knapp Martin, Baldwin Ashley, Clive Ballard, Peter Bentham, Brown, Richard, McKeith, Ian, Brown, Richard; id_orcid, Juszczak Ed, Phillips Patrick, James Raftery, E. Juszczak (7589267), Burns, A, Howard Rob, Banerjee, Sube, Macharouthu, Ajay, Passmore, P, Brown Richard, Jones, R, Hughes Alan, Gray, Richard, Phillips, P, R. Jacoby (7589288), J. O'Brien (7608797), Phillips, P., Macharouthu Ajay, A. Burns (842688), R. Howard (1274091), Juszczak, Edmund, C. Holmes (7589285), Howard, Rob, M. Griffin (3933326), Macharouthu, A, M. Knapp (2534038), Jones, R. G., C. Ballard (7608770), Passmore, Peter, Johnson, T, Rob Howard, Holmes Clive, Sheehan Bart, Findlay, David, Rupert McShane, Jacoby, R, James Lindesay, Johnson, T., Hughes, A., Craig Ritchie, Howard, Robert, Jones, Roy W., O'Brien, J. T., David Findlay, R. McShane (7608791), Howard, R, Tom Dening, Onions Caroline, Holmes, Clive, McKeith Ian, Lindesay, J, Johnson Tony, Gray Richard, Barber Bob, I. McKeith (7608788), Ritchie, C, Burns Alistair, Adams, J., T. Johnson (7602368), A. Macharouthu (7608794), Johnson, Tony, Lindesay James, McKeith, I. G., A. Hughes (7190519), Jones, Rob, Banerjee Sube, Bentham Peter, Hughes, A, Lindesay, James, Raftery, J. P., Adams Jessica, Mary Griffin, Onions, Caroline, Griffin, Mary, C. Ritchie (7608806), Onions, C, Peter Passmore, John O'Brien, Baldwin, Ashley, Sheehan, B, Adams, J, Burns, Alistair, Jacoby Robin, Burns, Alistair S., Griffin, M., Passmore Peter, Roy Jones, R. Jones (3979994), Ballard, Clive, C. Onions (7608764), Bentham, P, Findlay, D, O'Brien, J, B. Barber (7608773), R. Gray (7608782), Martin Knapp, Caroline Onions   +175 more
core   +1 more source

The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer’s disease patients: study protocol for a randomized controlled trial

Trials, 2017
Background Alzheimer’s disease is a progressive neurodegenerative disease. Although some of the current treatments offer some symptomatic relief, this disease cannot be cured at present.
Weina Peng, Jing Zhou, Min Xu, Qing Feng, Lulu Bin, Zhishun Liu   +5 more
doaj   +1 more source

Clinicial and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review [PDF]

, 2001
Background Alzheimer’s disease is the most common cause of dementia and is characterised by an insidious onset and slow deterioration. The estimated prevalence of Alzheimer’s disease for a standard health authority (500,000 people) is about 3330. Current
A. Clegg, N. Waugh, S. De Broe, Gerard, K., Bryant, J., K. Gerard, Clegg, A. J., McIntyre, Linda, L. McIntyre, Bryant, Jackie, Gerard, Karen, Waugh, Norman, McIntyre, L., Nicholson, T., T. Nicholson, De Broe, S., Clegg, A., Waugh, N., J. Bryant   +18 more
core   +1 more source

Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice

Molecules, 2021
The pharmacokinetic (PK) change in a drug by co-administered herbal products can alter the efficacy and toxicity. In the circumstances that herb–drug combinations have been increasingly attempted to alleviate Alzheimer’s disease (AD), the PK evaluation ...
Mingoo Bae, Seung Yon Han, Eun-Sun Kim, Byung Hoon You, Young-Mi Kim, Jungsook Cho, Young-Won Chin, Young Hee Choi   +7 more
doaj   +1 more source

Donepezil suppresses intracellular Ca2+ mobilization through the PI3K pathway in rodent microglia

Journal of Neuroinflammation, 2017
Background Microglia are resident innate immune cells which release many factors including proinflammatory cytokines or nitric oxide (NO) when they are activated in response to immunological stimuli. Pathophysiology of Alzheimer’s disease (AD) is related
Yoshinori Haraguchi, Yoshito Mizoguchi, Masahiro Ohgidani, Yoshiomi Imamura, Toru Murakawa-Hirachi, Hiromi Nabeta, Hiroshi Tateishi, Takahiro A. Kato, Akira Monji   +8 more
doaj   +1 more source

Donepezil improves vascular function in a mouse model of Alzheimer’s disease

Pharmacology Research & Perspectives, 2021
Cardiovascular complications in Alzheimer's disease (AD) patients can occur years to decades prior to the onset of clinical symptoms of the disease. Donepezil represents the most effective drug in the treatment of AD.
Carolina Pellegrini, Vanessa D’Antongiovanni, Matteo Fornai, Emiliano Duranti, Filippo Baldacci, Nunzia Bernardini, Stefano Taddei, Agostino Virdis, Corrado Blandizzi, Stefano Masi, Luca Antonioli   +10 more
doaj   +1 more source

Donepezil-induced psychosis: a cautionary report of a rare adverse reaction

European Psychiatry, 2023
Introduction Donepezil is an acetylcholinesterase inhibitor approved by the Food and Drug Administration for the treatment of dementia in Alzheimer’s disease. While it is not curative for Alzheimer’s disease, donepezil has been shown to improve symptoms
K. R. Hutchings, B. K. Hutchings, B. Ratnakaran, A. S. Kablinger   +3 more
doaj   +1 more source

Therapeutic drug monitoring of rivastigmine and donepezil under consideration of CYP2D6 genotype-dependent metabolism of donepezil [PDF]

, 2020
Background: The efficacy of acetylcholinesterase inhibitors (AChE-I) might depend on blood concentration. While rivastigmine metabolism is independent of the cytochrome P450 system, its isoenzymes, especially CYP2D6, metabolize donepezil.
Schneider, Heike, Bürger, Katharina, Ortner, Marion, Buerger, Katharina, Diehl-Schmid, Janine, Schroeder, Charlotte, Schröder, Charlotte, Müller, Claudia, Grimmer, Timo, Förstl, Hans, Steimer, Werner, Müller-Sarnowski, Felix, Stange, Marion   +12 more
core   +1 more source

Evaluation of the Binding Characteristics of [5-11C-methoxy]Donepezil in the Rat Brain for In Vivo Visualization of Acetylcholinesterase

Journal of Pharmacological Sciences, 2003
Donepezil, an acetylcholinesterase (AChE) inhibitor, has not been evaluated for its binding characteristics using a radioactive tracer, although its inhibitory action on AChE has been studied.
Yoshihito Funaki, Motohisa Kato, Ren Iwata, Eiko Sakurai, Eiichi Sakurai, Manabu Tashiro, Tatsuo Ido, Kazuhiko Yanai   +7 more
doaj   +1 more source